RE:RE:RE:Hemerion Planning Phase 2 Trial at Mt. Sinai NY in 2022Thanks Eog - to you and GoJo.
Orphan status makes sense in relation to the high cost of developing effective treatments for relatively low volume but nonetheless devastating diseases.It sensibly encourages research by Companies who in the event of success can expect to be not only compensated but fairly rewarded but it is a question of degree.
Is 10 years` really a reasonable timescale during which to exclude other possibly superior photosensitisers from being used in the same indication irrespective of how much more effective they might prove to be? Is it realistic that having given such explicit incentive they are likely to leave themselves open to the legal consequences of over-ruling it?
Perhaps my expectations for the future behaviour of this particular insitution have been jaundiced by their most recent use of medicine as a political football but it will be interesting to see how this may play out.